Literature DB >> 6126111

Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol.

L H Opie, L Jee, D White.   

Abstract

The calcium-channel blocker, nifedipine, was used as additional oral therapy to beta-adrenergic receptor blockade by the cardioselective agent, atenolol, in the therapy of 31 patients with hypertension. Initial studies were directed towards control of associated angina pectoris in 15 of the patients, but no effects were found on angina except in two patients. However, arterial blood pressure was consistently reduced in all patients. Further studies on 16 patients were therefore directed towards the use of nifedipine as an antihypertensive agent in addition to atenolol and a thiazide diuretic. Nifedipine (10 mg sublingually) acutely dropped blood pressure by about 30/20 mm Hg (systolic/diastolic) within 20 minutes. Follow-up studies made after 4 to 8 weeks showed that the initial acute response to nifedipine predicted the long-term response to oral nifedipine, 10 mg twice daily. Of 31 hypertensive patients tested, only one failed to respond to nifedipine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126111     DOI: 10.1016/0002-8703(82)90234-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  19 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  Nifedipine as low-dose monotherapy for essential hypertension: a primary care study.

Authors:  L D Ritchie; L T Harrington; A R MacGregor; M J Vandenburg
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 5.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise.

Authors:  M R Wilkins; K L Woods; D B Jack; M J Kendall; S J Laugher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension.

Authors:  L D Jee; L H Opie
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

8.  Effect of nifedipine and propranolol on blood flow, venous compliance and blood pressure in essential hypertension.

Authors:  R I Ogilvie
Journal:  Can Med Assoc J       Date:  1985-05-15       Impact factor: 8.262

9.  The effect of ageing on the disposition of nifedipine and atenolol.

Authors:  M Scott; C M Castleden; H K Adam; R P Smith; T J Fitzsimons
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

10.  Interactions of a new beta-blocker, celiprolol, with the calcium antagonists, diltiazem and nifedipine, on atrioventricular conduction.

Authors:  S Motomura; K Hashimoto
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.